← Back to headlines
H.C. Wainwright Raises Price Target on Aktis Oncology (AKTS) to $33
H.C. Wainwright has increased its price target for Aktis Oncology (AKTS) to $33, reflecting a more favorable outlook for the company's stock.
12 Apr, 21:18 — 12 Apr, 21:18
Sources
Showing 1 of 1 sources
Related Stories
Amazon's First Customer Receipt Goes Viral, Bezos and Musk React
just now
Philippines Central Bank Offers Loan Relief Amid Middle East Crisis Fallout
just now
Philippine Court Inspects 'Ghost Project' in Revilla Corruption Case
just now
Philippine COA Affirms Decision to Flag OVP Confidential Funds
just now